Navigation Links
Pregis Announces First Quarter 2009 Financial Results
Date:5/12/2009

f acquisitions: Accounts and other receivables, net 15,908 3,671 Due from Pactiv - 5,165 Inventories, net 1,314 (8,276) Prepayments and other current assets 329 (554) Accounts payable (11,442) 10,782 Accrued taxes (2,127) (5,400) Accrued interest 3,936 4,538 Other current liabilities (140) (4,006) Pension and related assets and liabilities, net (926) (1,035) Other, net 256 302 --- --- Cash provided by operating activities 8,397 15,071 ----- ------ Investing activities Capital expenditures (5,096) (10,863) Proceeds from sale of assets 266 - Other, net - 63 --- --- Cash used in investing activities (4,830) (10,800) ------ ------- Financing activities Repayment of long-term debt (446) (488) Other, net (119) 1,731 ---- ----- Cash (used in) provided by financing activities (565) 1,243 Effect of exchange rate changes on cash and cash equivalents (1,825) 2,008 ------ ----- Increase in cash and cash equivalents 1,177 7,522 Cash and cash equivalents, beginnin
'/>"/>
SOURCE Pregis Corporation
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. Pregis Corporation Appoints New President of Protective Packaging North America
2. Pregis Announces Investor Conference Call to Review 2007 Fourth Quarter and Full Year Financial Results
3. Pregis Announces Fouth Quarter and Full Year 2007 Financial Results
4. Pregis Announces First Quarter 2008 Financial Results
5. Pregis Announces Second Quarter 2008 Financial Results
6. Pregis Announces Investor Conference Call to Review 2008 Third Quarter Financial Results
7. Pregis Announces Third Quarter 2008 Financial Results
8. Pregis Announces Investor Conference Call to Review Fourth Quarter and Full Year 2008 Financial Results
9. Pregis Announces Fourth Quarter and Full Year 2008 Financial Results
10. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
11. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 2Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 3Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 4Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 5Hill-Rom Announces Appointment of James R. Giertz to Board of Directors 2The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 2The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 3The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 4The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 5CRF announces late breaking trials to be presented at TCT 2009 in San Francisco 54339 1CRF announces late breaking trials to be presented at TCT 2009 in San Francisco 54339 2CRF announces late breaking trials to be presented at TCT 2009 in San Francisco 54339 3National Cancer Institute names Emory to nationwide NCI chemical biology consortium 54337 1National Cancer Institute names Emory to nationwide NCI chemical biology consortium 54337 2National Cancer Institute names Emory to nationwide NCI chemical biology consortium 54337 3National Cancer Institute names Emory to nationwide NCI chemical biology consortium 54337 4Accera Announces Peer Reviewed Publication of the Results of its 90 Day Clinical Study of AC 1202 28Axona 28TM 29 29 in Mild to Moderate Alzheimers 13530 1Accera Announces Peer Reviewed Publication of the Results of its 90 Day Clinical Study of AC 1202 28Axona 28TM 29 29 in Mild to Moderate Alzheimers 13530 2Accera Announces Peer Reviewed Publication of the Results of its 90 Day Clinical Study of AC 1202 28Axona 28TM 29 29 in Mild to Moderate Alzheimers 13530 3